As July concludes, the landscape of hematologic oncology continues to evolve, with notable progress in multiple myeloma, ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

UK-listed pharmaceutical company plans to bring four more speciality medicines to late-stage clinical trials this year ...

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that ...

The FTSE 100 enjoyed another leap towards record territory as the index pushed around 0.7 per cent higher on Tuesday, ...

Investing.com -- GSK (LON: GSK) on Wednesday raised its full-year earnings guidance after posting a 35% rise in ...

SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...

The FTSE 100 has ticked up this morning after what became a wobbly session on Monday, with a stack of fresh earnings updates helping traders early on Tuesday. Entain and Games Workshop are leading ...

Antibody-drug conjugates are a growing class of biopharmaceuticals that combine the precision of monoclonal antibodies with ...

GSK is expected to report profit of £4.4 billion for the first half of this year. AstraZeneca is forecast to report a ...